Waverly Advisors 13F: Adds $2.7M to Amgen (AMGN) Stake

Waverly Advisors Expands Position in Amgen Inc.

Institutional investor Waverly Advisors lifted its stake in Amgen Inc. (NasdaqGS: AMGN) by 21.6% during the quarter, according to a Form 13F filing with the U.S. Securities and Exchange Commission. The firm purchased an additional 7,344 shares of the healthcare company, bringing its total ownership to 41,386 shares. Based on market prices, the reported value of the position reached approximately $14.9 million.

How Waverly Adjusted Its Amgen Holdings

The reported transaction grew Waverly's investment from its prior count of 34,042 shares. Because 13F filings are backward-looking snapshots reflecting holdings at the close of a previous quarter, the filing shows past portfolio adjustments and may not capture current trading activity.

Amgen Stock Trades Near Mid-Range Levels

Shares of Amgen changed hands at $361.17 on the stock market. Over the past year, the equity has moved between a low of $288.00 and a high of $447.03. The company carries a trailing price-to-earnings ratio of 27.0, while trading with a market capitalization exceeding $234 billion.

Recent Analyst Updates on Amgen

Research firms recently reviewed their stances on the biotechnology company. On October 13, 2026, Guggenheim kept a neutral rating while adjusting its target to $378.00. BMO Capital maintained a market perform rating with a $415.00 target on October 12, 2026. Wells Fargo kept an equal-weight rating on the same day at a $430.00 target. UBS maintained a buy rating on October 9, 2026, lifting its target to $470.00. RBC Capital kept an outperform rating on October 8, 2026, with a $430.00 target, and Cantor Fitzgerald held a neutral rating at a $440.00 target. Truist Securities kept a hold rating on October 7, 2026, at $380.00, while Morgan Stanley kept an equal-weight rating at $359.00. Across the broader community, the stock holds a consensus hold recommendation and a mean price target of $394.98.

Inside Amgen Operations

Amgen discovers, develops, and manufactures human therapeutics for serious illnesses. The company markets treatments for rheumatoid arthritis, plaque psoriasis, bone health, cardiovascular risks, and various oncology indications worldwide. It distributes these medicines through wholesale channels and maintains key collaboration agreements with major industry partners.

What to Watch Next for Amgen

Investors tracking the healthcare giant will look ahead to its upcoming earnings report scheduled for November 3, 2026. Future SEC filings from institutional managers will also reveal whether firms like Waverly Advisors continue adjusting their positions in the drugmaker.